

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/631,411	09/631,411 08/03/2000		Xu Cao	D6258	9593
7	7590	06/05/2002			
Benjamin Aa			EXAMINER		
McGregor & A 8011 Candle L	ane	,	ZARA, JANE J		
Houston, TX 77071			ART UNIT	PAPER NUMBER	
				1635	
				DATE MAILED: 06/05/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

		ATTORNEY DOCKET NO.
<u> </u>	7	EXAMINER
	ART	TUNIT : PAPER NUMBER

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

PLEASE See **Commissioner of Patents and Trademarks**

Page 2

Application/Control Number: 09/631,411

Art Unit: 1635

<u>Attachment</u>

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Please provide appropriate accompanying nucleotide sequences and SEQ Id Nos. for the nucleic acids described in the specification and the claims (i.e. for Hoxc-8, Smad1, Smad4 and Smad6 disclosed in figures 1-4 and in the claims).

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Application/Control Number: 09/631,411

Art Unit: 1635

Conclusion

Page 3

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(703)** 306-5820. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (703) 308-0447. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (703) 305-3413. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JZ

June 3, 2002

J Zaa TC1606

the many of
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
The nucleotide and/or amino acid sequence disclosure contained in this application does not
comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for ${ m t}$
Comply with the requirements for such a disclosure as set for the rest of the 1.021 - 1.025 for the
following reason(s):
·
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's
attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR
18230, May 1, 1990.
, , , , , , , , , , , , , , , , , , ,
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence
2. This application does not contain, as a separate part of the disclosure on paper copy, a "sequence
Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by
37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the
content of the computer readable form does not comply with the requirements of 37 C.F.R. 1,822
and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
and the set as maistred on the addition only of the mained appropriate Coquence Country.
The computer readable form that has been fled with this application has been found to the
5. The computer readable form that has been filed with this application has been found to be damaged
and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute
computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the
"Sequence Listing" as required by 37 C.F.R. 1.821(e).
0/ 12 00 111 000 00 00 00 00
7 7. Other: PLEASE OFOUIDE APPROPRIATE SEQ 5
7. Other: PLEASE Provide Appropriate Sep's For Nucleie Acids Smad 1, 4, 7 + Applicant Must Provide: HOXC-8.
FOR NUCLEIE ACIDS SMADI, 4, 7 4
HOXC-8.
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
A serior of anomaly company to the contract of
~
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry
into the specification.
A statement that the content of the paper and computer readable copies are the same and, where
applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or
1.825(b) or 1.825(d).
•

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support (SIRA)

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE